To Claim or Reclaim? Universal Influenza Vaccines Present Market Opportunity for Current and New Players Alike

The development of universal influenza vaccines is presenting an ideal opportunity for pharmaceutical manufacturers to enter into, or differentiate themselves within, a crowded marketplace, although they must first be prepared to handle the high R&D costs involved, says an analyst with research and consulting firm GlobalData.
Although the influenza vaccine sector has previously demonstrated a stagnant activity pipeline, a recent study proposes that medicine consisting of core viral proteins may elicit cellular responses that are protective against multiple strains of the virus.
Robert Wilson, GlobalData’s Healthcare Analyst covering Infectious Disease, believes that such vaccines could represent the “ultimate step” in a long-term trend towards expanded coverage, while allowing players both current and new to stake their claims in the vaccine market, which GlobalData estimates at $2.2 billion annually across the seven major markets (the US, France, Germany, Italy, Spain, Japan and the UK).
He says: “The ability to protect against any strain of influenza would put universal vaccines in a strong position to capitalise on outbreaks of pandemic influenza, offering the potential to merge the seasonal and pandemic vaccine markets.
“However, scalable production technologies, such as cell culture-based methodologies, would be needed to produce vaccines quickly in response to outbreaks, and companies might therefore be required to increase their R&D investment to take full advantage of the opportunity that universal flu vaccines offer.”
Although Wilson believes that such significant costs will prove a major barrier to vaccine development, he suggests that companies must leverage public-private partnerships (PPPs) and government funding so as to reduce these expenses as much as possible.
He continues: "Universal flu vaccines do indeed present a significant risk for pharmaceutical manufacturers, because of the high costs involved, but they also offer extremely large rewards.
“For instance, as well as providing a chance for new companies to enter the sector without having to compete directly with established manufacturers, they also come with an anticipated premium price that will prove an attractive option for both current and future players looking to progress with R&D activity.”
In the meantime, Wilson believes that companies that have already innovated in quadrivalent vaccines are set to take advantage of their investment over the coming years; for example, GlobalData has estimated that Sanofi’s Fluzone QIV could earn as much as $375 million in 2014.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance